2025-11-13T12:19:44-06:00 2025-06-30 991856619 GRANT THORNTON ADVISORS LLC 1000 WILSON BOULEVARD SUITE 1500 ARLINGTON VA 22209 990 2024-07-01 131656692 UNITED STATES PHARMACOPEIAL CONVENTION UNIT 3018810666 12601 TWINBROOK PARKWAY ROCKVILLE MD 20852 STANLEY D BURHANS CFO & SVP, OPERATIONS 3018810666 2025-11-12 1 0 MARY TORRETTA P00847851 7038477500 2024 2025-03-06 01:10:19Z RONALD T PIERVINCENZI 12601 TWINBROOK PARKWAY ROCKVILLE MD 20852 585231368 0 X WWW.USP.ORG X 1820 MD TO IMPROVE THE HEALTH OF PEOPLE AROUND THE WORLD THROUGH PUBLIC STANDARDS AND (SEE SCHEDULE O) RELATED PROGRAMS THAT HELP ENSURE THE QUALITY, SAFETY, AND BENEFIT OF MEDICINES AND FOODS. 13 13 941 657 53797 0 31691692 23758628 311282673 312085057 10536524 21655407 238438 221552 353749327 357720644 498078 523834 0 0 177358807 181392116 0 0 1009323 152480768 151698998 330337653 333614948 23411674 24105696 750835911 788657741 188101832 182029433 562734079 606628308 X USP'S MISSION IS TO IMPROVE GLOBAL HEALTH THROUGH PUBLIC STANDARDS AND RELATED PROGRAMS THAT HELP ENSURE THE QUALITY, SAFETY, AND BENEFIT OF MEDICINES AND FOODS. 0 0 205689189 0 304315984 COMPENDIAL ACTIVITIES - SEE SCHEDULE O 26780945 0 2473381 NON-COMPENDIAL ACTIVITIES - SEE SCHEDULE O 5122424 523834 5295692 ALLIED COMPENDIAL ACTIVITIES - SEE SCHEDULE O 237592558 1 1 0 1 0 0 0 0 0 0 1 1 0 1 1 1 0 1 0 1 1 1 1 0 0 0 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 1 X 188 0 1 941 1 1 1 1 BR CH ET GH IN SN SZ CA UK LU BG KE LI NP RW PK NI 0 0 0 0 0 0 0 0 0 0 X 13 13 0 0 0 0 1 1 1 1 1 0 0 1 1 1 1 1 1 1 1 1 1 MD IL X STANLEY D BURHANS 3019986781 12601 TWINBROOK PARKWAY ROCKVILLE MD 20852 DENNIS E DOHERTY MD CONVENTION PRESIDENT 4.00 0.00 X X 0 0 0 TODD K ABRAHAM PHD MBA TREASURER 4.00 0.00 X X 0 0 0 GREGORY E AMIDON PHD PHARMACEUTICAL SCIENCES TRUSTEE 4.00 0.00 X 0 0 0 GWEN DARIEN PUBLIC TRUSTEE 4.00 0.00 X 0 0 0 RICHARD J GILFILLAN MD MBA AT LARGE TRUSTEE 4.00 0.00 X 0 0 0 JESSE L GOODMAN MD MPH MEDICAL SCIENCES TRUSTEE 4.00 0.00 X 0 0 0 LAURA HERMAN MBA MA AT LARGE TRUSTEE 4.00 0.00 X 0 0 0 THOMAS MENIGHAN BSPHARMMBA AT LARGE TRUSTEE 4.00 0.00 X 0 0 0 KRISHNA REDDY NALLAMALLA MD AT LARGE TRUSTEE 4.00 0.00 X 0 0 0 STEPHEN OSTROFF MD MEDICAL SCIENCES TRUSTEE 4.00 0.00 X 0 0 0 JULIO SANCHEZ Y TEPOZ MSCSJD AT LARGE TRUSTEE 4.00 0.00 X 0 0 0 JOHN TAYLOR JD AT LARGE TRUSTEE 4.00 0.00 X 0 0 0 SUSAN WINCKLER RPH JD CHAIR AND PHARMA SCI TRUSTEE 4.00 0.00 X 0 0 0 RONALD T PIERVINCENZI CHIEF EXECUTIVE OFFICER & EX-OFFICIO 38.00 0.00 X 975149 0 129385 JAKOB VENEMA TO 625 EVP & CHIEF SCIENCE OFFICER 38.00 0.00 X 618546 0 89510 ANTHONY P LAKAVAGE SECRETARY & SVP GLBL EA 38.00 0.00 X 545170 0 83094 AMANDA D COWLEY SVP, LEGAL, STRATEGY & PEOPLE 38.00 0.00 X 530651 0 77892 STANLEY D BURHANS CHIEF FINANCIAL OFFICER 38.00 0.00 X 507875 0 81657 EMILY M KAINE SVP, GBL HEALTH & MANUFACTURING SVCS 38.00 0.00 X 527212 0 52400 BRUK ALEMAYEHU SVP, GLOBAL LAB & TECHNICAL OPS 38.00 0.00 X 430208 0 52515 JENNIFER DEVINE SVP, DOC STDS & COMP POLICY 38.00 0.00 X 419352 0 31585 JOHN A GIANNONE TO 824 VP, COMPENDIAL OPERATIONS 38.00 0.00 X 552057 0 58652 VENKAT SURENDRA NATH KODURU SVP REGIONS & PROGRAM OPS.(TO 6/25) 38.00 0.00 X 490928 0 37430 DEBRA J PEREZ CHIEF EQUITY OFFICER 38.00 0.00 X 449620 0 69136 MICHAEL S LEVY SVP, DIGITAL & INNOVATION 38.00 0.00 X 441812 0 44939 FOUAD ATOUF SVP, SCI-GLOB BIO 38.00 0.00 X 424410 0 51808 6912990 0 860003 683 0 1 0 RUDER FINN INC 425 E 53RD ST NEW YORK NY 10022 CONSULTING 2776905 VELOCITY GLOBAL LLC 3858 WALNUT ST STE 107 DENVER CO 80205 CONSULTING 2390094 ERNST & YOUNG LLP 1101 NEW YORK AVE NW WASHINGTON DC 20005 CONSULTING 2066599 ABM INDUSTRY GROUPS LLC ONE LIBERTY PLAZA 7TH FLOOR NEW YORK NY 10006 FACILITIES SERVICES 1978299 BELL TECHLOGIX INC 4400 WEST 96TH ST INDIANAPOLIS IN 46268 IT SERVICES 1587324 60 21952739 1805889 1805889 23758628 COMPENDIAL ACTIVITIES 423490 304315984 304315984 ALLIED COMPENDIAL ACT. 423490 5295692 5295692 NON-COMPENDIAL ACT. 423490 2473381 2419584 53797 312085057 10074561 10074561 129204 129204 239091570 227405976 104748 11685594 -104748 11580846 11580846 MISCELLANEOUS REVENUE 900099 92348 92348 92348 357720644 312031260 53797 21876959 X 293187 293187 80645 80645 150002 150002 6912990 3104924 3658421 149645 140514004 101233664 38685684 594656 13077593 9255412 3756157 66024 10985178 7774546 3155172 55460 9902351 7008196 2844162 49993 343147 343147 456840 456840 258010 258010 1173322 1173322 27106900 19420980 7596538 89382 730650 506808 220124 3718 8241960 7315079 926842 39 17678048 3597832 14080216 5669751 2032012 3637739 5289739 4570009 719324 406 2646116 2358295 287821 2908601 2908601 36507699 33789673 2718026 11051342 5338533 5712809 1297370 1297370 COST OF GOODS SOLD 20651102 20651102 VALIDATION &CALIBRATION 3453263 3308979 144284 PUB/SUBSCRIPTIONS 2341050 2252674 88376 EXHIBITS 218809 139106 79703 3675279 3410900 264379 333614948 237592558 95013067 1009323 28514480 37786886 31131585 25941585 7154593 828848 48602810 44606175 69203646 65737416 12988689 10830119 248253399 128289706 126101073 119963693 291583862 321616701 77660533 86881986 57894640 74464332 750835911 788657741 69885754 69379739 7404393 8208573 87329897 82673571 23481788 21767550 188101832 182029433 X 562734079 606628308 562734079 606628308 750835911 788657741 X 24105696 19282462 506071 X 0 1 X 1 1 1 X 12769050 23282824 30105843 31691692 23758628 121608037 303225858 303193655 305130377 311282673 312031260 1534863823 315994908 326476479 335236220 342974365 335789888 1656471860 0 0 0 1656471860 4069196 9158226 10111352 10061446 10203765 43603985 4069196 9158226 10111352 10061446 10203765 43603985 53797 53797 78336 437557 9818 92348 618059 320064104 335713041 345785129 353045629 346139798 1700747701 0.97400 0.97620 0.02560 0.02350 X SCHEDULE A, PART III, LINE 12, EXPLANATION OF OTHER INCOME: OTHER INCOME - 2020 AMOUNT: $ 0. 2021 AMOUNT: $ 78,336. 2022 AMOUNT: $ 437,557. 2023 AMOUNT: $ 9,818. 2024 AMOUNT: $ 92,348. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 258010 258010 333356938 333614948 1000000 250000 0 0 1000000 1000000 1000000 1000000 4000000 6000000 369423 228200 222178 258010 1077811 250000 250000 250000 250000 1000000 1500000 SCHEDULE C, PART II-A USP ENGAGES WITH PAID LOBBYISTS TO SECURE GOVERNMENTAL FUNDING WHICH IS THEN USED TO FURTHER USP'S TAX-EXEMPT MISSION. 9389846 9389846 137418298 55693425 81724873 19848241 10684283 9163958 48087678 36646474 11441204 33509336 25265524 8243812 119963693 ALTERNATIVE INVESTMENTS 86881986 F 86881986 INVESTMENT IN SUBSIDIARIES 42623613 INTERCOMPANY/SUBSIDIARY LOAN RECEIVABLES 16847630 RIGHT OF USE (LEASE) ASSET 14993089 74464332 LEASE LIABILITIES 20714727 OTHER LONG-TERM LIABILITIES 1052823 21767550 X PART X, LINE 2: USPC FOLLOWS GUIDANCE THAT CLARIFIES THE ACCOUNTING FOR UNCERTAINTY IN TAX POSITIONS TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN, INCLUDING ISSUES RELATING TO CONSOLIDATED FINANCIAL STATEMENT RECOGNITION AND MEASUREMENT. THIS GUIDANCE PROVIDES THAT THE TAX EFFECTS FROM AN UNCERTAIN TAX POSITION CAN ONLY BE RECOGNIZED IN THE CONSOLIDATED FINANCIAL STATEMENTS IF THE POSITION IS "MORE-LIKELY-THAN-NOT" TO BE SUSTAINED IF THE POSITION WERE TO BE CHALLENGED BY A TAXING AUTHORITY. THE ASSESSMENT OF THE TAX POSITION IS BASED SOLELY ON THE TECHNICAL MERITS OF THE POSITION, WITHOUT REGARD TO THE LIKELIHOOD THAT THE TAX POSITION MAY BE CHALLENGED. 1 SOUTH AMERICA 1 10 PROGRAM SERVICES COMPENDIAL 2161289 EAST ASIA AND THE PACIFIC 2 20 PROGRAM SERVICES COMPENDIAL 4348031 SOUTH ASIA 1 368 PROGRAM SERVICES COMPENDIAL 21156987 SUB-SAHARAN AFRICA 1 1 PROGRAM SERVICES COMPENDIAL 2003563 EUROPE (INCLUDING ICELAND & 1 4 PROGRAM SERVICES SALES OFFICE 2941145 SOUTH ASIA 1 1 PROGRAM SERVICES PQM OFFICE/USAID 185899 EAST ASIA AND THE PACIFIC 1 6 PROGRAM SERVICES SALES OFFICE 1153900 SUB-SAHARAN AFRICA 5 2 PROGRAM SERVICES PQM OFFICE/USAID 2737405 EAST ASIA AND THE PACIFIC 1 0 PROGRAM SERVICES PQM OFFICE/USAID 837231 SOUTH ASIA 1 0 PROGRAM SERVICES PQM OFFICE/USAID 688859 SUB-SAHARAN AFRICA INVESTMENTS 1081604 EAST ASIA AND THE PACIFIC INVESTMENTS 2857806 EUROPE (INCLUDING ICELAND & INVESTMENTS 1854252 SOUTH AMERICA INVESTMENTS 2348113 SOUTH ASIA INVESTMENTS 17719311 EUROPE (INCLUDING ICELAND & GRANTMAKING 143732 SUB-SAHARAN AFRICA GRANTMAKING 6270 13 412 2 0 15 412 36688219 27537178 64225397 MIDDLE EAST AND NORTH AFRICA DRUG INFORMATION ASSOCIATION CONFERENCE 2024 6270 WIRE TRANSFER 0 1 USP GLOBAL FELLOWSHIP PROGRAM EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIU 1 140287 WIRE TRANSFER 0 1 0 1 0 0 1 PART I, LINE 2: PROCEDURES FOR MONITORING THE USE OF GRANTS OUTSIDE U.S. USP WILL ESTABLISH A SPECIFIC REPORTING PROCESS AND TIMING WITH EACH FOREIGN ORGANIZATION AND INDIVIDUAL WHO RECEIVES A GRANT. THE REPORTING METHODOLOGY AND TIMING OF THE REPORTS WILL CARRY ON A PER GRANT BASIS. AT A MINIMUM, THE GRANTEE WILL BE EXPECTED TO PROVIDE A NARRATIVE STATEMENT AS TO THE PROGRESS MADE IN ACCOMPLISHING THE PURPOSE OF THE GRANT. PART I, LINE 3: ACCOUNTING METHOD USED THE EXPENDITURES, PER REGION, ARE PRESENTED ON THE ACCRUAL BASIS OF ACCOUNTING. 1 ASSOCIATION FOR ACCESSIBLE MEDICINES 601 NEW JERSEY AVE NW STE 850 WASHINGTON DC 20001 522252820 501(C)(6) 32700 0 SPONSORSHIP - AAM 2024 GRX+ BIOSIMS AMERICAN PHARMACISTS ASSOCIATION ATT ACCOUNTS RECEIVABLE WASHINGTON DC 200372985 526039142 501(C)(3) 27737 0 APHA 2025 ANNUAL MEETING - SPONSORSHIP PROJECT HOPE KENDRA E DAVENPORT MILLWOOD VA 22646 530242962 501(C)(3) 25000 0 INAUGURAL CHARITY GOLF TOURNAMENT SPONSORSHIP BIOHEALTH INNOVATION INC 1 CHURCH STREET STE 801 ROCKVILLE MD 20850 453824067 501(C)(3) 25000 0 CHARITABLE DONATION NEWARK MENTORING MOVEMENT 60 PARK PLACE NEWARK NJ 07102 453824067 501(C)(3) 20000 0 NEWARK MENTORING MOVEMENT GEORGE WASHINGTON'S MOUNT VERNON 3200 MOUNT VERNON MEMORIAL HIGHWAY MOUNT VERNON VA 22121 540564701 501(C)(3) 19500 0 CHARITABLE DONATION REAGAN UDALL FOUNDATION FOR THE FOOD AND DRUG ADMINISTRATION INC 1900 L ST NW WASHINGTON DC 20036 263727917 501(C)(3) 15000 0 ANNUAL INNOVATIONS IN REGULATORY SCIENCE AWARDS - SPONSORSHIP WORLDWIDE BUSINESS RESEARCH USA LLC 535 FIFTH AVE NEW YORK NY 10017 223709362 LLC 12000 0 LOGIPHARMA US 2024 MEETING - SPONSORSHIP ALLIANCE FOR AGING RESEARCH 1700 K ST NW STE 740 WASHINGTON DC 20006 541379174 501(C)(3) 10000 0 ANNUAL DINNER SPONSORSHIP CONSUMER HEALTH PRODUCTS ASSOCIATION 1625 EYE ST NW WASHINGTON DC 20006 200689578 501(C)(3) 10000 0 PLATINUM LEVEL SPONSORSHIP MARYLAND TECHNOLOGY COUNCIL INC 9700 GREAT SENECA HIGHWAY ROCKVILLE MD 20850 521807245 501(C)(6) 10000 0 BIO MTC SILVER LEVEL SPONSORSHIP NATIONAL CONSUMERS LEAGUE PO BOX 759339 BALTIMORE MD 212759339 530242038 501(C)(3) 10000 0 SPONSORSHIP NCL TRUMPETER AWARDS DINNER AMERICAN ASSOCIATION OF PHARMACEUTICAL SCIENTISTS KENDLE INTERNATIONAL INC CINCINNATI OH 45202 521444968 501(C)(3) 10000 0 AAPS 2024 PHARMSCI 360 MEETING - SPONSORSHIP AMERICAN SOCIETY OF GENE AND CELL THERAPY 555 E WELLS ST STE 100 MILWAUKEE WI 53202 911766321 501(C)(3) 8600 0 ASGCR ANNUAL MEETING - SPONSORSHIP ARTHRITIS FOUNDATION INC 1355 PEACHTREE ST STE 600 ATLANTA GA 30309 581341679 501(C)(3) 8000 0 BRONZE LEVEL SPONSORSHIP AMERICAN BOTANICAL COUNCIL PO BOX 144345 AUSTIN TX 787144345 742518542 501(C)(3) 6900 0 GOLD SPONSOR MEMBERSHIP PANIC NMR ASSOCIATION INC 2512 DEEP CREEK RD PERKIOMENVILLE PA 18074 475577736 501(C)(3) 6000 0 2025 PANIC NMR CONFERENCE - SPONSORSHIP 14 3 USP GLOBAL FELLOWSHIP PROGRAM 2 80645 0 PART I, LINE 2: PROCEDURE FOR MONITORING USE OF GRANT FUNDS INSIDE U.S. USP HAS ESTABLISHED A SPECIFIC REPORTING PROCESS AND TIMING WITH EACH INDIVIDUAL GRANT RECIPIENT. THE REPORTING METHODOLOGY AND TIMING OF THE REPORTS WILL VARY ON A PER GRANT BASIS. AT A MINIMUM, THE GRANTEE WILL BE EXPECTED TO PROVIDE A NARRATIVE STATEMENT AS TO THE PROGRESS MADE IN ACCOMPLISHING THE PURPOSE OF THE GRANT. ORGANIZATIONS RECEIVING MONETARY SUPPORT FROM USP IN THE FORM OF SPONSORSHIP PROVIDE USP WITH ACKNOWLEDGEMENT OF THE RECEIPT AND CONFIRMATION THAT THE USES OF THE FUNDS PROVIDED WERE FOR THE STATED AND AGREED TO PURPOSE. X X X X 1 1 0 0 0 0 0 1 0 RONALD T PIERVINCENZI CHIEF EXECUTIVE OFFICER & EX-OFFICIO 760961 0 188946 0 25242 0 117452 0 11933 0 1104534 0 0 0 JAKOB VENEMA TO 625 EVP & CHIEF SCIENCE OFFICER 483831 0 108393 0 26322 0 75817 0 13693 0 708056 0 0 0 ANTHONY P LAKAVAGE SECRETARY & SVP GLBL EA 403592 0 115411 0 26167 0 74100 0 8994 0 628264 0 0 0 JOHN A GIANNONE TO 824 VP, COMPENDIAL OPERATIONS 173110 0 64616 0 314331 0 53500 0 5152 0 610709 0 0 0 AMANDA D COWLEY SVP, LEGAL, STRATEGY & PEOPLE 401705 0 103636 0 25310 0 65561 0 12331 0 608543 0 0 0 STANLEY D BURHANS CHIEF FINANCIAL OFFICER 382280 0 99428 0 26167 0 67397 0 14260 0 589532 0 0 0 EMILY M KAINE SVP, GBL HEALTH & MANUFACTURING SVCS 422519 0 102883 0 1810 0 42046 0 10354 0 579612 0 0 0 VENKAT SURENDRA NATH KODURU SVP REGIONS & PROGRAM OPS.(TO 6/25) 401346 0 85018 0 4564 0 30500 0 6930 0 528358 0 0 0 DEBRA J PEREZ CHIEF EQUITY OFFICER 344688 0 77868 0 27064 0 64063 0 5073 0 518756 0 0 0 MICHAEL S LEVY SVP, DIGITAL & INNOVATION 321248 0 77835 0 42729 0 36729 0 8210 0 486751 0 40642 0 BRUK ALEMAYEHU SVP, GLOBAL LAB & TECHNICAL OPS 341627 0 84172 0 4409 0 38255 0 14260 0 482723 0 0 0 FOUAD ATOUF SVP, SCI-GLOB BIO 344533 0 76710 0 3167 0 35070 0 16738 0 476218 0 0 0 JENNIFER DEVINE SVP, DOC STDS & COMP POLICY 345080 0 71950 0 2322 0 31510 0 75 0 450937 0 0 0 SCHEDULE J, PART I, LINE 4A: DURING THE YEAR JOHN A. GIANNONE RECEIVED A SEVERANCE PAYMENT OF $258,300. THIS PAYMENT IS REPORTED AS OTHER REPORTABLE COMPENSATION ON PART II, COLUMN B (III). SCHEDULE J, PART I, LINE 4B: SUPPLEMENTAL NONQUALIFIED RETIREMENT PLAN DURING THE YEAR, CERTAIN INDIVIDUALS PARTICIPATED IN A NONQUALIFIED RETIREMENT PLAN. THE FOLLOWING INDIVIDUAL RECEIVED DEFERRED COMPENSATION DISTRIBUTIONS REPORTED ON SCHEDULE J, PART II, COLUMN B(III), OTHER REPORTABLE COMPENSATION. MICHAEL S. LEVY: $40,642 THE FOLLOWING INDIVIDUALS RECEIVED DEFERRED CONTRIBUTIONS (UNPAID AND ELIGIBLE FOR PAYMENT BASED ON VESTING AND PAYOUT SCHEDULE) REPORTED ON SCHEDULE J, PART II, COLUMN C, RETIREMENT AND OTHER DEFERRED COMPENSATION: RONALD T. PIERVINCENZI: $63,952. JAKOB VENEMA: $28,392 ANTHONY LAKAVAGE: $20,600 AMANDA D. COWLEY: $19,561 EMILY M. KAINE: $19,046 STANLEY D. BURHANS: $17,397 VENKAT SURENDRA NATH KODURU: $14,829 DEBRA J. PEREZ: $10,563 BRUK ALEMAYEHU: $9,506 FOUAD ATOUF: $9,150 JENNIFER DEVINE: $7,210 MICHAEL S. LEVY: $6,229 NURISHA R. WADE: $3,081 KENNETH B. ALEXANDER: $3,013 SCHEDULE J, PART I, LINE 7: NON-FIXED PAYMENTS USP PROVIDES INCENTIVE COMPENSATION THAT IS COMMENSURATE WITH THE ACCOMPLISHMENT OF STATED GOALS. EACH INDIVIDUAL OFFICER, KEY EMPLOYEE, OR HIGHLY COMPENSATED EMPLOYEE HAS AN ANNUAL GOAL PLAN. BASED ON THE ACCOMPLISHMENT OF THOSE INDIVIDUAL STATED GOALS, THE INDIVIDUAL IS ELIGIBLE FOR A BONUS WHICH IS WITHIN A FIXED PERCENTAGE RANGE. BONUSES ARE CONSIDERED AS PART OF THE TOTAL COMPENSATION WHEN DETERMINING REASONABLENESS. A MARYLAND ECONOMIC DEVELOPMENT CORPORATION 521376562 000000000 2012-03-29 109360000 REFUND OF '08 & '09 TX-EX BONDS 0 0 0 A 26540000 109360000 4524 109355476 1 0 1 1 A 0 0 0 0 0 0 1 A 0 0 1 0 0 0 0 0 1 A 1 X RAW MATERIALS 97 1805889 REPLACEMENT COST 0 1 0 SCHEDULE M, PART I, COLUMN (B): NUMBER OF CONTRIBUTIONS THE NUMBERS LISTED IN PART I, COLUMN B, REFLECT THE NUMBER OF INDIVIDUAL CONTRIBUTIONS RECEIVED. FORM 990, PART III, LINE 4A: PROGRAM SERVICE ACCOMPLISHMENTS COMPENDIAL PROGRAMS - USP ESTABLISHES INTERNATIONALLY RECOGNIZED PUBLIC STANDARDS (BOTH DOCUMENTARY STANDARDS AND THE PHYSICAL REFERENCE MATERIALS THAT SUPPORT THE APPLICATION AND USE OF THESE DOCUMENTARY STANDARDS) TO HELP ENSURE GOOD QUALITY MEDICINES, DIETARY SUPPLEMENTS, FOOD INGREDIENTS, AND RELATED PRODUCTS USED TO MAINTAIN HEALTH AND TREAT DISEASE. THESE STANDARDS ARE DEVELOPED USING AN OPEN, PUBLIC PROCESS AND ARE APPROVED BY INDEPENDENT SCIENTIFIC EXPERTS. PRESCRIPTION AND OVER THE COUNTER MEDICINES AVAILABLE IN THE UNITED STATES MUST, BY FEDERAL LAW, MEET USP'S PUBLIC STANDARDS, WHERE SUCH STANDARDS EXIST. MANY OTHER COUNTRIES REQUIRE THE USE OF HIGH-QUALITY STANDARDS SUCH AS USP'S TO ENSURE THE QUALITY OF MEDICINES, FOOD INGREDIENTS, AND RELATED PRODUCTS. USP DISSEMINATES ITS STANDARDS TO PHARMACEUTICAL MANUFACTURERS, PHARMACISTS, FOOD MANUFACTURERS, AND OTHER USERS THROUGH ITS USP-NF, FOOD CHEMICALS CODEX (FCC), OTHER COMPENDIA AND PUBLICATIONS, AND OFFICIAL USP REFERENCE STANDARD MATERIALS. THESE STANDARDS ARE SHARED WITH OTHER COUNTRIES AROUND THE WORLD VIA THEIR DRUG REGULATORY AGENCIES AND COMPANIES. INCREASINGLY, DRUG REGULATORY AUTHORITIES IN OTHER COUNTRIES ARE RECEIVING ASSISTANCE FROM USP IN UNDERSTANDING HOW THEY CAN IMPROVE THE QUALITY OF MEDICINES PROVIDED TO THEIR CITIZENS BY USING USP STANDARDS. VOLUNTEER EXPERTS FROM THOSE COUNTRIES ARE ACTIVE PARTICIPANTS IN USP'S STANDARDS-SETTING BODIES. IN ADDITION, USP DEVELOPS STANDARDS THAT ARE VITAL TO ENSURING AND IMPROVING PATIENT SAFETY IN A VARIETY OF SETTINGS RELATED TO THE APPROPRIATE LABELING, STORAGE, DISTRIBUTION AND USE OF MEDICINES. HEALTH CARE CLINICIANS AS WELL AS PATIENTS RELY ON THESE STANDARDS TO HELP ENSURE THAT MEDICINES ARE DELIVERED AND USED APPROPRIATELY. FORM 990, PART III, LINE 4B: PROGRAM SERVICE ACCOMPLISHMENTS ALLIED COMPENDIAL PROGRAMS - USP CONDUCTS VERIFICATION PROGRAMS FOR PHARMACEUTICAL INGREDIENTS, AND FOR DIETARY SUPPLEMENT INGREDIENTS AND PRODUCTS. THESE PROGRAMS INVOLVE INDEPENDENT TESTING AND REVIEW TO VERIFY THE IDENTITY, STRENGTH, QUALITY AND PURITY OF INGREDIENTS AND PRODUCTS FOR MANUFACTURERS WHO CHOOSE TO PARTICIPATE. THEY HELP TO IMPROVE THE QUALITY OF MEDICINES AND DIETARY SUPPLEMENTS THAT ARE MANUFACTURED AND THEN PROVIDED TO PATIENTS AND CONSUMERS THROUGH THE GLOBAL SUPPLY CHAIN. USP CONDUCTS EDUCATIONAL CLASSES AND PROGRAMS FOR CHEMISTS, SCIENTISTS, AND HEALTHCARE PRACTITIONERS IN THE UNITED STATES AND AROUND THE WORLD. USP SEEKS TO IMPROVE THE EFFECTIVE USE OF ITS STANDARDS THAT AFFECT BEST PRACTICES IN MANUFACTURING AND REGULATION OF PHARMACEUTICALS, DIETARY SUPPLEMENTS, AND FOOD INGREDIENTS. FORM 990, PART III, LINE 4C: PROGRAM SERVICE ACCOMPLISHMENTS NON-COMPENDIAL - USP'S GLOBAL HEALTH DIVISION CONTRIBUTES TO IMPROVED GLOBAL HEALTH BY ENSURING THE AVAILABILITY OF RELEVANT PUBLIC STANDARDS FOR THE WORLD'S MOST ESSENTIAL MEDICINES, SUPPORTING THE GLOBAL MANUFACTURING SECTOR TO INCREASE THE SUPPLY OF QUALITY ASSURED MEDICINES, AND STRENGTHENING NATIONAL AND REGIONAL REGULATORY SYSTEMS TO SUPPORT IMPROVED QUALITY ASSURANCE SYSTEMS, GLOBALLY. USP IMPLEMENTED ITS PROMOTING THE QUALITY OF MEDICINES (PQM PLUS) PROGRAM IN COOPERATION WITH USAID, TO HELP THE QUALITY OF MEDICINES IN MORE THAN 30 COUNTRIES AROUND THE WORLD. THROUGH OUR ADVANCED TRAINING AND LABORATORY FACILITY IN GHANA, USP SUPPORTED WORKFORCE DEVELOPMENT IN AFRICA TO SUPPORT CONTINUED IMPROVEMENT OF PHARMACEUTICAL QUALITY ASSURANCE AND QUALITY CONTROL EFFORTS IN THE REGION. THE PQM PLUS PROGRAM WAS EARLY TERMINATED FOLLOWING THE ISSUANCE OF A STOP-WORK ORDER BY USAID IN FISCAL YEAR 2025. USP MAINTAINS FOUR REGIONAL NETWORKS OF OFFICIAL MEDICINES CONTROL LABORATORIES (NOMCOL) WHICH HELP BUILD REGIONAL COOPERATION AND SUSTAINABLE CAPACITY FOR ONGOING EFFORTS TO ASSURE THE QUALITY OF MEDICINES, GLOBALLY. USP STANDARDS ARE MADE AVAILABLE TO REGULATORS IN LOWER AND MIDDLE INCOME COUNTRIES AT NO COST, OR AT SHARPLY DISCOUNTED COST. IN ADDITION, USP PROVIDES DIRECT TECHNICAL ASSISTANCE THROUGH A NUMBER OF OTHER GLOBAL HEALTH IMPACT PROGRAMS. USP ENGAGES IN OTHER PUBLIC HEALTH INITIATIVES INCLUDING SERVING AS THE SECRETARIAT FOR A MAJOR GROUP OF OTHER NON-PROFIT ORGANIZATIONS THAT JOIN TO COORDINATE PATIENT SAFETY/MEDICAL ERROR EFFORTS. UNDER FEDERAL LAW, ONE OF USP'S HEALTH CARE INFORMATION INITIATIVES IS THE DEVELOPMENT OF A DRUG CLASSIFICATION SYSTEM THAT MEDICARE PRESCRIPTION DRUG BENEFIT PLANS MAY USE TO DEVELOP THEIR FORMULARIES. FORM 990, PART VI, SECTION A, LINE 6 MEMBERS OR STOCKHOLDERS THE MEMBERS OF THE USP CONVENTION ARE REPRESENTATIVES FROM ORGANIZATIONS IN THE US AND ABROAD IN THE FOLLOWING CATEGORIES: - HEALTH PRACTITIONER PROFESSIONAL AND SCIENTIFIC ASSOCIATIONS - CONSUMER AND OTHER PUBLIC INTEREST ORGANIZATIONS - MANUFACTURER, TRADE, AND AFFILIATED ASSOCIATIONS - GOVERNMENTAL BODIES, DIVISIONS, OR ASSOCIATIONS - NON-GOVERNMENT STANDARDS-SETTING AND CONFORMITY ASSESSMENT BODIES - ACADEMIC INSTITUTIONS AND ASSOCIATIONS FORM 990, PART VI, SECTION A, LINE 7A MEMBERS OR STOCKHOLDERS WHO MAY ELECT AND DECISIONS SUBJECT TO APPROVAL THE MEMBERS OF USP ELECT THE MEMBERS OF THE BOARD OF TRUSTEES AT EACH FIVE-YEAR MEETING OF THE CONVENTION. UP TO THREE ADDITIONAL TRUSTEES MAY BE APPOINTED BY THE BOARD DURING THE FIVE-YEAR CYCLE. GOVERNANCE DECISIONS OF THE ORGANIZATION RESERVED TO MEMBERS INCLUDE ELECTING THE BOARD OF TRUSTEES (BOT) AND THE COUNCIL OF EXPERTS (COE) AS WELL AS AMENDING BYLAWS AND ADOPTING RESOLUTIONS. FORM 990, PART VI, SECTION A, LINE 7B SEE EXPLANATION FOR FORM 990, PART VI, LINE 7A FORM 990, PART VI, SECTION B, LINE 11B FORM 990 REVIEW PROCESS THE FORM 990 WAS REVIEWED BY THE CHIEF FINANCIAL OFFICER AND PRESENTED TO CURRENT USP OFFICERS AS WELL AS THE AUDIT COMMITTEE AND APPROVED BY THE FULL BOARD PRIOR TO FILING WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C CONFLICT OF INTEREST POLICY MONITORING & ENFORCEMENT USP'S CONFLICT OF INTEREST POLICY IS REFLECTED IN ITS BYLAWS AND IN ITS CODE OF ETHICS. THIS POLICY IS IMPLEMENTED WITH RESPECT TO OUR EMPLOYEES AND VOLUNTEERS (MEMBERS OF THE BOARD OF TRUSTEES AND THE COUNCIL OF EXPERTS AND EXPERT COMMITTEES, USP'S STANDARD SETTING BODIES) THROUGH SPECIFIC PROVISIONS IN THE EMPLOYEE HANDBOOK, THE RULES OF BUSINESS PRACTICE FOR THE BOARD OF TRUSTEES, AND THE RULES AND PROCEDURES OF THE COUNCIL OF EXPERTS. ALL TRUSTEES, MEMBERS OF THE COUNCIL OF EXPERTS AND EXPERT COMMITTEES, AND EMPLOYEES IN DIRECTOR LEVEL OR ABOVE POSITIONS OR POSITIONS WHERE THEY WORK WITH EXPERT COMMITTEES OR OTHER EXTERNAL STAKEHOLDERS (INCLUDING STAFF WHO FREQUENTLY INTERACT WITH CUSTOMERS AND OTHER THIRD PARTIES) ARE REQUIRED TO SUBMIT AND KEEP CURRENT A DISCLOSURE STATEMENT IDENTIFYING ANY CONFLICT OF INTEREST. FOR USP'S VOLUNTEERS, A CONFLICT OF INTEREST IS DEFINED BROADLY UNDER THE BYLAWS TO INCLUDE A FINANCIAL INTEREST IN A COMPANY OR ANY OTHER RELATIONSHIP OR INTEREST THAT COULD INTERFERE WITH THE INDIVIDUAL'S ABILITY TO EXERCISE INDEPENDENT JUDGMENT. TRUSTEES, EXPERTS AND EMPLOYEES ARE REQUIRED TO RECUSE THEMSELVES FROM ANY MATTER IN WHICH THEY HAVE A POTENTIAL CONFLICT, AND EMPLOYEES MAY ALSO BE REQUIRED TO DIVEST THEMSELVES OF INTERESTS THAT PRESENT A POTENTIAL CONFLICT. THE IDENTIFICATION AND RESOLUTION OF CONFLICTS OF INTEREST IS HANDLED AS FOLLOWS FOR USP EMPLOYEES AND VOLUNTEERS: EMPLOYEES: DISCLOSURE STATEMENTS ARE COLLECTED ANNUALLY BY THE GLOBAL COMPLIANCE AND ETHICS DEPARTMENT FROM EMPLOYEES AT THE DIRECTOR LEVEL AND ABOVE OR WHO OTHERWISE HOLD A POSITION IN WHICH THE EMPLOYEE ACTIVELY PARTICIPATES IN THE STANDARDS-SETTING PROCESS OR A POSITION IN WHICH AN EMPLOYEE REGULARLY INTERACTS WITH EXTERNAL STAKEHOLDERS SUCH AS THOSE WITH EXTERNAL, DONOR FUNDED, OR CUSTOMER DEVELOPMENT RESPONSIBILITIES. IF AN EMPLOYEE DISCLOSES THAT HE OR SHE HAS A FINANCIAL INTEREST ABOVE THE SPECIFIED THRESHOLD, THE SENIOR DIRECTOR, GLOBAL COMPLIANCE REVIEWS THE INTEREST WITH THE CEO. IF THE CEO DETERMINES THAT THE INTEREST IS AN ISOLATED ONE AND ONE THAT WOULD BE DIFFICULT TO DIVEST (E.G., A RETIREMENT PLAN FROM A FORMER EMPLOYER, OR A SPOUSE'S EMPLOYMENT), THE EMPLOYEE IS ALLOWED TO RETAIN THE INTEREST BUT MUST RECUSE HIMSELF/HERSELF IN ANY SITUATION WHERE THERE IS A POTENTIAL CONFLICT. IN OTHER CASES, SUCH AS WHERE THERE ARE MULTIPLE INTERESTS ABOVE THE THRESHOLD, THE CEO MAY ASK THE EMPLOYEE TO DIVEST. MEMBERS OF THE BOARD OF TRUSTEES: DISCLOSURE STATEMENTS ARE COLLECTED BY THE SECRETARY, AND THE BOARD MEMBERS HAVE AN OBLIGATION TO UPDATE THEM AS NECESSARY TO KEEP THEM CURRENT. IF A BOARD MEMBER HAS A POTENTIAL CONFLICT, THEN IN ACCORDANCE WITH THE BYLAWS HE OR SHE SHALL NOTIFY THE BOARD OR EXPERT COMMITTEE PRIOR TO DELIBERATION ON THE MATTER IN QUESTION, AND SUCH BODY SHALL MAKE THE FINAL DETERMINATION AS TO WHETHER THE INDIVIDUAL HAS A CONFLICT OF INTEREST IN ANY MATTER. THE MINUTES OF THE APPLICABLE MEETING SHALL REFLECT DISCLOSURE AND RESOLUTION OF ANY CONFLICT OF INTEREST, INCLUDING ANY ABSTENTION OR RECUSAL, DUE TO CONFLICT OF INTEREST. COUNCIL OF EXPERTS AND EXPERT COMMITTEE MEMBERS: DISCLOSURE STATEMENTS ARE COLLECTED BY THE EXECUTIVE SECRETARIAT, AND MEMBERS HAVE AN OBLIGATION TO UPDATE THEM AS NECESSARY TO KEEP THEM CURRENT. THE CHAIR OF EACH EXPERT COMMITTEE, WORKING WITH STAFF (SCIENTIFIC LIAISON/EXECUTIVE SECRETARIAT), HAS RESPONSIBILITY FOR RESOLVING CONFLICT ISSUES. FORM 990, PART VI, SECTION B, LINE 15 PROCESS FOR DETERMINING COMPENSATION THE USP BOARD OF TRUSTEES APPROVED A TOTAL COMPENSATION PHILOSOPHY WITH THE FOLLOWING KEY PROVISIONS: 1. USP WILL LINK BASE PAY AND VARIABLE PAY TO PERFORMANCE IN SUCH A WAY THAT IT ALIGNS WITH USP'S STRATEGIC PLANNING PROCESS AND OUTCOME-BASED METRICS, AND RESULTS IN DIFFERENTIAL REWARDS. 2. USP WILL CONTINUALLY EVALUATE AND REALIGN PERFORMANCE MEASURES TO CONFORM TO CHANGING STRATEGIC GOALS AND OTHER BUSINESS NEEDS. 3. USP'S TOTAL CASH COMPENSATION PROGRAM WILL BE DESIGNED USING A MARKET-DRIVEN WHOLE JOB FAMILY STRUCTURE TO DELIVER ABOVE AVERAGE TOTAL COMPENSATION, DIRECT AND INDIRECT, RELATIVE TO THOSE OFFERED WITHIN VARIOUS LABOR MARKETS IN WHICH USP COMPETES FOR TALENT. THE TOTAL COMPENSATION PACKAGE WILL BE ESTABLISHED, REVIEWED, AND APPROVED IN A MANNER THAT QUALIFIES FOR THE REBUTTABLE PRESUMPTION OF REASONABLENESS AND WILL BE REVIEWED PERIODICALLY TO ENSURE THAT IT CONTINUES TO BE ALIGNED WITH USP'S STRATEGIC DIRECTION AND FINANCIAL LIMITS AND CONTINUES TO BE BOTH REASONABLE AND COMPETITIVE. UNDER THE RULES OF BUSINESS PRACTICE OF THE BOARD OF TRUSTEES IS RESPONSIBLE FOR OVERSEEING THE ORGANIZATION'S COMPENSATION AND BENEFITS SYSTEMS AND PROGRAMS, INCLUDING: - REVIEWING AND MAKING RECOMMENDATIONS TO THE BOARD REGARDING THE OVERALL COMPENSATION PHILOSOPHY AND PRINCIPLES OF THE ORGANIZATION. - REVIEWING THE STRUCTURE OF THE STAFF COMPENSATION PROGRAM, INCLUDING SALARY LEVELS, BENEFITS, AND THE SUCCESS SHARING PLAN AND THE EXTENT TO WHICH THEY ARE ACHIEVING DESIRED PURPOSES. - REVIEWING AND MAKING RECOMMENDATIONS TO THE EXECUTIVE COMMITTEE AND THE BOARD REGARDING EMPLOYEE BENEFIT PLANS AND EMPLOYEE BENEFITS, WITH THE BOARD RETAINING RESPONSIBILITY FOR FINAL APPROVAL OF THE INSURER OR INSURERS THROUGH WHOSE POLICIES THE PLAN BENEFITS ARE TO BE FUNDED AND THE RULES AND PROCEDURES FOR ADMINISTRATION OF THE PLAN. - BASED ON INPUT FROM THE CEO REVIEWING AND MAKING RECOMMENDATIONS TO THE BOARD REGARDING THE PROPOSED METRICS FOR ORGANIZATIONAL PERFORMANCE UNDER THE SUCCESS SHARING PLAN, AND THE ACHIEVEMENT OF SUCH METRICS. FORM 990, PART VI, SECTION C, LINE 19 HOW DOCUMENTS ARE MADE AVAILABLE TO THE PUBLIC USP MAKES THESE DOCUMENTS AVAILABLE TO THE PUBLIC TO THE EXTENT REQUIRED BY LAW AND UPON REQUEST. FORM 990, PART IX, LINE 11G PROFESSIONAL SERVICES: PROGRAM SERVICE EXPENSES 12,718,957. MANAGEMENT AND GENERAL EXPENSES 6,010,011. FUNDRAISING EXPENSES 87,321. TOTAL EXPENSES 18,816,289. AGENCY TEMPS: PROGRAM SERVICE EXPENSES 5,218,550. MANAGEMENT AND GENERAL EXPENSES 1,128,508. FUNDRAISING EXPENSES 2,061. TOTAL EXPENSES 6,349,119. CONSULTING: PROGRAM SERVICE EXPENSES 1,202,080. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 1,202,080. RECRUITMENT: PROGRAM SERVICE EXPENSES 31,728. MANAGEMENT AND GENERAL EXPENSES 433,502. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 465,230. TRAINING: PROGRAM SERVICE EXPENSES 249,665. MANAGEMENT AND GENERAL EXPENSES 24,517. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 274,182. FORM 990, PART XI, LINE 9: INTERCOMPANY ELIMINATION ADJUSTMENT 1,191,884. UNREALIZED GAIN ON FOREIGN EXCHANGE -693,631. ELIMINATION OF INTERCOMPANY PAYABLES 7,818. USP HOLDING LLC 12601 TWINBROOK PARKWAY ROCKVILLE MD 20852 562515663 HOLDING MD 39362030 29335406 USP USP HOLDING INTERNATIONAL LLC 12601 TWINBROOK PARKWAY ROCKVILLE MD 20852 562515662 HOLDING MD 0 0 USP UNITED STATES PHARMACOPEIA - GHANA NO3 PARK AVE MOTORWAY EXTN ACCRA GH WY 1204 131656692 PHARMACEUTICAL TRAINING GH FOREIGN USP HOLDING 1 PHARMATECH ASSOCIATES INC 22320 FOOTHILL BLVD SUITE 330 HAYWARD CA 94541 943347981 SCIENTIFIC CA USP HOLDING C 5889391 636500 1.00000 1 STRATIX LABS CORPORATION 1000 WEST GATE DR STE 132 ST PAUL MN 55114 474148412 SCIENTIFIC MN USP HOLDING C 284162 10111600 1.00000 1 US PHARMACOPEIA INDIA PRIVATE LTD ICICI KNOWLEDGE PARK GENOME VALLEY HYDERBAD IN 500 131656692 SCIENTIFIC IN USPHUSPHI C 23733636 30699008 1.00000 1 US PHARMACOPEIA NIGERIA LTDGTE 2 CONNAL ROAD LAGOS NI SCIENTIFIC NI USPC C 674661 9260 1.00000 1 US PHARMACOPEIA STND RESEARCH & DEV WAIGAOQIAO FREE TRADE 520 NFU TE SHANGHAI CH 200131 131656692 SCIENTIFIC CH USP HOLDING C 4603121 2149370 1.00000 1 US PHARMACOPEIA SWITZERLAND AG MUNCHENSTEINERSTRASSE 41 BASEL SZ 4052 131656692 SCIENTIFIC SZ USP HOLDING C 3235259 5621804 1.00000 1 US PHARMACOPEIA-SINGAPORE PTELTD 37TH FL SING 50 RAFFLES PLACE STE SINGAPORE SN 048623 131656692 SCIENTIFIC SN USP HOLDING C 1206992 1377049 1.00000 1 UNITED STATES FARMACOPEIA BRASIL LTDA WTORRE TECHNOLOGY PARK AVENIDA CECI SAO PAULO BR N 1 131656692 SCIENTIFIC BR USPHUSPHI C 2059798 2722174 1.00000 1 USP KENYA OFFICE NO 8 MUGUMO GARDENS 90 JA NAIROBI LAVINGTON KE 131656692 SCIENTIFIC KE USP HOLDING C 773330 380332 1.00000 1 US PHARMACOPEIAL CONVENTION SHANGHAI REP OFFICE ROOM 801-804 BLDG B NO 999 ZHOU SHANGHAI CH 200137 SCIENTIFIC CH USPC C 6607 1.00000 1 1 1 0 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 0 UNITED STATES FARMACOPEIA BRASIL LTDA F 223687 FMV US PHARMACOPEIA STND RESEARCH & DEV F 1080000 FMV UNITED STATES FARMACOPEIA BRASIL LTDA M 210654 FMV US PHARMACOPEIA STND RESEARCH & DEV M 464949 FMV US PHARMACOPEIA INDIA PRIVATE LTD M 4858380 FMV UNITED STATES PHARMACOPEIA - GHANA M 1230782 FMV US PHARMACOPEIA-SINGAPORE PTELTD M 1051149 FMV US PHARMACOPEIA SWITZERLAND AG M 5164551 FMV USP KENYA M 283787 FMV PHARMATECH ASSOCIATES INC M 36176 FMV US PHARMACOPEIA INDIA PRIVATE LTD Q 99056 FMV UNITED STATES PHARMACOPEIA - GHANA Q 251540 FMV US PHARMACOPEIA SWITZERLAND AG Q 3291886 FMV USP KENYA Q 490112 FMV STRATIX LABS CORPORATION Q 274904 FMV PHARMATECH ASSOCIATES INC D 10850000 FMV US PHARMACOPEIA INDIA PRIVATE LTD D 4997630 FMV STRATIX LABS CORPORATION D 1000000 FMV US PHARMACOPEIA STND RESEARCH & DEV R 2000000 FMV UNITED STATES PHARMACOPEIA - GHANA R 12480000 FMV US PHARMACOPEIA INDIA PRIVATE LTD R 6460904 FMV UNITED STATES FARMACOPEIA BRASIL LTDA R 595664 FMV US PHARMACOPEIA-SINGAPORE PTELTD R 837993 FMV US PHARMACOPEIA SWITZERLAND AG R 101667 FMV PHARMATECH ASSOCIATES INC R 16642383 FMV STRATIX LABS CORPORATION R 9238427 FMV US PHARMACOPEIA INDIA PRIVATE LTD A 114822 FMV PHARMATECH ASSOCIATES INC A 826338 FMV STRATIX LABS CORPORATION A 27037 FMV